Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

World Journal of Gastroenterology

Volumn 14, Issue 24, 2008, Pages 3879-3883

  Al Moundhri, Mansour S ^a   Al Shukaili, A ^a   Al Nabhani, M ^a   Al Bahrani, B ^b   Burney, I A ^a   Rizivi, A ^a   Ganguly, S S ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b ROYAL HOSPITAL   (Oman)

Author keywords

Gastric cancer; Oman; Serum; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL RATE; TUMOR DIFFERENTIATION;

EID: 54349098298     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3879     Document Type: Article

References (30)

1. Anderson C, Nijagal A, Kim J. Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 2006: 10: 345-352
2. Al-Moundhri MS, Al-Bahrani B, Burney IA, Nirmala V, Al-Madhani A, Al-Mawaly K, Al-Nabhani M, Thomas V, Ganguly SS, Grant CS. The prognostic determinants of gastric cancer treatment outcome in Omani Arab patients. Oncology 2006; 70: 90-96
3. Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya N, Itoh A, Hirooka Y, Goto H. Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol 2007; 22: 1435-1442
4. Barchielli A, Amorosi A, Balzi D, Crocetti E, Nesi G. Long-term prognosis of gastric cancer in a European country: a population-based study in Florence (Italy). 10-year survival of cases diagnosed in 1985-1997. Eur J Cancer 2001; 37: 1674-1680
5. Al-Moundhri MS, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly SS, Grant C. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol 2005; 91: 243-252
6. Mihmanli M, Dilege F, Demir U, Coskun H, Froglu T, Uysalol MD. The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology 2004; 51: 1544-1547
7. Boku N, Ohtsu A, Yoshida S, Shirao K, Shimada Y, Hvodo I, Saito H, Miyata Y. Significance oi biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol 2007; 37: 275-281
8. Hormbrey E, Gillespie P, Turner K, Han C, Roberts A, McGrouther D, Harris AL. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002; 19: 651-663
9. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007; 38: 258-268
10. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition - a critical review. Anticancer Agents Med Chem 2007; 7: 223-245
11. Simiantonaki N, Taxeidis M, Jayasinghe C, Kirkpatrick CJ. Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status. Anticancer Res 2007; 27: 3245-3250
12. Zhao HC, Qin R, Chen XX, Sheng X, Wu JF, Wang DB, Chen GH. Microvessel density is a prognostic marker of human gastric cancer. World J Gastroenterol 2006; 12: 7598-7603
13. Zhou Y, Ran J, Tang C, Wu J, Honghua L, Xingwen L, Ning C, Qiao L. Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther 2007; 6: 269-275
14. Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 2005; 8: 155-163
15. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236: 37-42
16. Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim CO, Kim SJ, Jeong JS, Kim HJ. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008; 8: 123
17. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic marker in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-240
18. Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007; 13: 1794-1797, discussion 1797-1798
19. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 2006: 16: 405-411
20. Ding S, Lin S, Deng X, Yang X, Qu H, Huang S, Liu W, Zhou L, Liu D. Potential prognostic value of circulating levels of vascular endothelial growth factor-A in pitients with gastric cancer. In ViVo 2005; 19: 793-795
21. Ohta M, Konno H, Tanaka I, Baba M, Kamiya K, Syoup T, Kondoh K, Watanabe M, Terada H, Nakamura S. The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer. Cancer Lett 2003; 192: 215-225
22. George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, Swift RI. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001; 3: 420-427
23. Kondo K, Kaneko T, Baba M, Konno H. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol Pharm Bull 2007; 30: 633-637
24. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 2006; 24: 576-580
25. Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ. Serum vascular endothelial growth factor in breast cancer. Anticancer Res 2007; 27: 3481-3487
26. Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, Dicuonzo G, Rocci L, Rosaria VM, Gebbia N, Tonini G. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 2007; 8: 319-327
27. Poon RT, Lau CP, Cheung ST, Yu WC, Fan Sr. Quantitative correlation of serum levels and tumor expression of vascular-endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003; 63: 3121-3126
28. Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbanska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 2003; 14: 149-153
29. Poreba M, Jazwiec B, Kuliczkowski K, Poreba R. [Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas] Pol Arch Med Wewn 2005; 113: 27-34
30. Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B. Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev 2002; 11: 245-252